Viracta Therapeutics Analyst Ratings
Viracta Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a maintained with a price target of $7.00 to $6.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.62, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 860.31% | RBC Capital | $7 → $6 | Maintains | Outperform |
| 10/05/2023 | 1020.36% | RBC Capital | → $7 | Reiterates | Outperform → Outperform |
| 08/15/2023 | 1020.36% | RBC Capital | → $7 | Reiterates | Outperform → Outperform |
| 08/15/2023 | 700.26% | SVB Securities | $10 → $5 | Maintains | Outperform |
| 08/15/2023 | 1500.51% | HC Wainwright & Co. | $10 → $10 | Reiterates | Buy → Buy |
| 07/31/2023 | 1500.51% | EF Hutton | → $10 | Initiates Coverage On | → Buy |
| 07/05/2023 | 1500.51% | HC Wainwright & Co. | $33 → $10 | Reiterates | Buy → Buy |
| 05/10/2023 | 5181.69% | HC Wainwright & Co. | $35 → $33 | Maintains | Buy |
| 05/09/2023 | 1020.36% | RBC Capital | $8 → $7 | Maintains | Outperform |
| 05/08/2023 | 1660.56% | SVB Securities | $11 → $11 | Maintains | Outperform |
| 03/27/2023 | 2460.82% | Oppenheimer | $14 → $16 | Maintains | Outperform |
| 03/14/2023 | 1180.41% | RBC Capital | → $8 | Reiterates | → Outperform |
| 03/14/2023 | 5501.79% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 11/11/2022 | 1180.41% | RBC Capital | $10 → $8 | Maintains | Outperform |
| 11/10/2022 | 1660.56% | SVB Securities | → $11 | Maintains | Outperform |
| 05/03/2021 | 5501.79% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 04/26/2021 | 2780.92% | SVB Leerink | → $18 | Initiates Coverage On | → Outperform |
| 03/25/2021 | 7102.3% | Evercore ISI Group | → $45 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/10/2023 | 860.31% | 加拿大皇家銀行資本 | 7 美元 → 6 美元 | 維護 | 跑贏大盤 |
| 10/05/2023 | 1020.36% | 加拿大皇家銀行資本 | → 7 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 08/15/2023 | 1020.36% | 加拿大皇家銀行資本 | → 7 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 08/15/2023 | 700.26% | SVB 證券 | 10 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 08/15/2023 | 1500.51% | HC Wainwright & Co. | 10 美元 → 10 美元 | 重申 | 購買 → 購買 |
| 07/31/2023 | 1500.51% | EF Hutton | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/05/2023 | 1500.51% | HC Wainwright & Co. | 33 美元 → 10 美元 | 重申 | 購買 → 購買 |
| 05/10/2023 | 5181.69% | HC Wainwright & Co. | 35 美元 → 33 美元 | 維護 | 買 |
| 05/09/2023 | 1020.36% | 加拿大皇家銀行資本 | 8 美元 → 7 美元 | 維護 | 跑贏大盤 |
| 05/08/2023 | 1660.56% | SVB 證券 | 11 美元 → 11 美元 | 維護 | 跑贏大盤 |
| 03/27/2023 | 2460.82% | 奧本海默 | 14 美元 → 16 美元 | 維護 | 跑贏大盤 |
| 03/14/2023 | 1180.41% | 加拿大皇家銀行資本 | → 8 美元 | 重申 | → 跑贏大盤 |
| 03/14/2023 | 5501.79% | HC Wainwright & Co. | → 35 美元 | 重申 | → 購買 |
| 11/11/2022 | 1180.41% | 加拿大皇家銀行資本 | 10 美元 → 8 美元 | 維護 | 跑贏大盤 |
| 2022 年 10 月 11 日 | 1660.56% | SVB 證券 | → 11 美元 | 維護 | 跑贏大盤 |
| 05/03/2021 | 5501.79% | HC Wainwright & Co. | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/26/2021 | 2780.92% | SVB Leerink | → 18 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 3 月 25 日 | 7102.3% | Evercore ISI 集團 | → 45 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Viracta Therapeutics (VIRX)?
Viracta Therapeutics（VIRX）的目標價格是多少？
The latest price target for Viracta Therapeutics (NASDAQ: VIRX) was reported by RBC Capital on November 10, 2023. The analyst firm set a price target for $6.00 expecting VIRX to rise to within 12 months (a possible 860.31% upside). 14 analyst firms have reported ratings in the last year.
加拿大皇家銀行資本於2023年11月10日公佈了Viracta Therapeutics（納斯達克股票代碼：VIRX）的最新目標股價。該分析公司將目標股價定爲6.00美元，預計VIRX將在12個月內升至12個月內（可能上漲860.31％）。去年有14家分析公司公佈了評級。
What is the most recent analyst rating for Viracta Therapeutics (VIRX)?
分析師對Viracta Therapeutics（VIRX）的最新評級是多少？
The latest analyst rating for Viracta Therapeutics (NASDAQ: VIRX) was provided by RBC Capital, and Viracta Therapeutics maintained their outperform rating.
加拿大皇家銀行資本對Viracta Therapeutics（納斯達克股票代碼：VIRX）的最新分析師評級由加拿大皇家銀行資本提供，Viracta Therapeutics維持跑贏大盤的評級。
When is the next analyst rating going to be posted or updated for Viracta Therapeutics (VIRX)?
Viracta Therapeutics（VIRX）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Viracta Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Viracta Therapeutics的最新評級是在2023年11月10日公佈的，因此您應該預計下一個評級將在2024年11月10日左右公佈。
Is the Analyst Rating Viracta Therapeutics (VIRX) correct?
分析師對Viracta Therapeutics（VIRX）的評級是否正確？
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a maintained with a price target of $7.00 to $6.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.62, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Viracta Therapeutics（VIRX）評級維持不變，目標股價爲7.00美元至6.00美元。Viracta Therapeutics（VIRX）目前的交易價格爲0.62美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。